Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Agentix Corp. is a clinical-stage biotechnology company focused on developing novel therapeutics for metabolic diseases, including type 2 diabetes, obesity, and non-alcoholic fatty liver disease. Its pipeline features peripherally-restricted cannabinoid receptor 1 antagonists designed to avoid central nervous system side effects. Agentix aims to advance early clinical development and partner with larger biopharma firms for commercialization, targeting a global market affected by metabolic syndrome.
This description was generated via AI from an annual report. Updated about 1 year ago.